Biotech and Pharmaceuticals
U.S. crude drops under $70 per barrel, fuel selling prices drop to 11-thirty day period very low
Fuel price ranges at a Shell gas station in Washington, DC, US, on Tuesday, Nov. 28, 2023. Al Drago | Bloomberg | Getty Visuals U.S. crude declined virtually 4% on Wednesday with retail gasoline selling prices hitting the most affordable position due to the fact January ahead of the holiday getaway browsing and journey year. […]
Read More
Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and Wegovy Courtesy: Eli Lilly Eli Lilly on Tuesday said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S., serving as an alternative to rival obesity drugs such as Wegovy that are facing supply issues. Zepbound is […]
Read More
CVS to change how it prices prescription drugs with new pharmacy reimbursement model
A sign outside a CVS Health store in Miami, Aug. 1, 2023. Joe Raedle | Getty Images CVS Health on Tuesday said will revamp how it prices prescription drugs and scrap a complex model that typically sets how much pharmacies get reimbursed and what patients pay for those medications. The new effort makes CVS the […]
Read More
Free ChatGPT may incorrectly answer drug questions, study says
Harun Ozalp | Anadolu | Getty Images The free version of ChatGPT may provide inaccurate or incomplete responses — or no answer at all — to questions related to medications, which could potentially endanger patients who use OpenAI’s viral chatbot, a new study released Tuesday suggests. Pharmacists at Long Island University who posed 39 questions […]
Read More
Roche enters obesity market with Carmot takeover but medications could not be accessible until finally 2030
BRAZIL – 2021/11/26: In this photograph illustration a F. HoffmannLa Roche AG logo is found on a screen and a hand keeping a capsule. (Picture Illustration by Rafael Henrique/SOPA Visuals/LightRocket by way of Getty Pictures) Sopa Photos | Lightrocket | Getty Photos Swiss prescribed drugs giant Roche is established to purchase anti being overweight drug […]
Read More
Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flops
Sopa Images | Lightrocket | Getty Images Pfizer’s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese patients taking the drug […]
Read More
Why Pfizer’s latest stumble in the obesity market is a boon for Eli Lilly
Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron, after patients in a mid-stage trial experienced […]
Read More
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. The drugmaker observed high rates of adverse side effects, which were mostly mild and gastrointestinal, among patients. A significant […]
Read More
Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs
A 0.25 mg injection pen of Novo Nordisk’s weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August 31, 2023. Victoria Klesty | Reuters Novo Nordisk on Thursday said it sued two compounding pharmacies in Florida for allegedly selling impure and “potentially unsafe” drugs claiming to contain semaglutide, the active ingredient in […]
Read More
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. Dado Ruvic | Reuters Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. Shares of ImmunoGen jumped more than 80% on Thursday, putting it on track for its highest […]
Read More